Redmile Biopharma Investments II, L.P.
Redmile Group · adviser of record: Redmile Group, LLC · 2018 vintage
Redmile Biopharma Investments II, L.P. is a 2018 venture fund managed by Redmile Group, with $675mm raised (Form D, amount sold). It reported $828mm in gross assets at year-end 2023, 1.23x its size, against a peak of $1.39bn in 2020.
- Latest value held
- $828mm year-end 2023
- Peak
- $1.39bn year-end 2020
- Fund size
- $675mm Form D, amount sold
- Held vs. size
- 1.23x peak 2.06x
Value held by year-end
Gross asset value reported on Form ADV at each year-end. Dashed line: fund size. Open in the Fund Tracker
| Year-end | Gross assets | ÷ size | Change |
|---|---|---|---|
| 2023 | $828mm | 1.23x | +6% |
| 2022 | $779mm | 1.15x | -31% |
| 2021 | $1.13bn | 1.67x | -19% |
| 2020 | $1.39bn | 2.06x | +107% |
| 2019 | $674mm | 1.00x | – |
| 2018 | $0k | 0.00x | – |
Other funds from Redmile Group
- Redmile Growth Investments I, L.P. 2021
- Raf, L.P. 2017
- Redmile Biopharma Investments I, L.P. 2014
- Redmile Private Investments II, L.P. 2014
- Redmile Private Investments I, L.P. 2012
About these numbers
Gross asset value is what the manager reports holding in the fund at each fiscal year-end, on SEC Form ADV, Schedule D. It includes the GP’s own commitment and is before carried interest, so it is not the LPs’ net return, and it does not show cash already distributed. A fall in value can mean distributions, markdowns or both. Fund size is the amount sold reported on Form D, which for some funds reflects only a first close. Private fund ID 805-9153149946. Data updated October 13, 2026.
Is this your fund?
Spot an error and email a correction. Facing DPI pressure? See how distribution financing works.